Mylan's most recent trend suggests a bearish bias. One trading opportunity on Mylan is a Bear Call Spread using a strike $57.50 short call and a strike $62.50 long call offers a potential 6.38% return on risk over the next 32 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $57.50 by expiration. The full premium credit of $0.30 would be kept by the premium seller. The risk of $4.70 would be incurred if the stock rose above the $62.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Mylan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Mylan is bearish.
The RSI indicator is at 38.3 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Mylan
Teva Upgraded On Strength Of Copaxone MS Drug
Fri, 12 Dec 2014 15:38:00 GMT
MiMedx Group, Conn's, Mylan, Pfizer and Amgen highlighted as Zacks Bull and Bear of the Day
Fri, 12 Dec 2014 15:22:44 GMT
Mylan Among First to Launch Generic Celebrex
Thu, 11 Dec 2014 20:22:23 GMT
Teva Pharm sees 2015 revenue lower than forecast
Thu, 11 Dec 2014 13:16:50 GMT
Reuters – UK Focus – Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. …
Mylan Launches Generic Robaxin® Injection
Thu, 11 Dec 2014 12:39:23 GMT
noodls – PITTSBURGH , Dec. 11, 2014 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product …
Also on Market Tamer…
Follow Us on Facebook